J. Pachter

Yan Wang, J. Pachter, M. Mulvihill, 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Ability of repetitive Ca2+ spikes to stimulate prolactin release is frequency dependent.

P. Dannies, J. Pachter, G. J. Law, 1989, Biochemical and biophysical research communications.

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity

P. Foden, R. Clarke, N. Bundred, 2021, NPJ breast cancer.

Regulation of phospholipid hydrolysis and second messenger formation by protein kinase C.

W. R. Bishop, J. Pachter, J. Pai, 1992, Advances in enzyme regulation.

Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.

C. Mullighan, P. Houghton, M. Churchman, 2016, JCI insight.

Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.

D. Werner, P. Gokhale, E. May, 2010, ACS medicinal chemistry letters.

c-Met Axis − miR-34 a − Mesotheliomas with Enriched Cancer Stem Cells via a p 53 Tumor Suppressor Alterations Cooperate to Drive Aggressive

Yue Wu, J. Testa, V. Kolev, 2014 .

Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.

Yue Wu, J. Testa, V. Kolev, 2014, Cancer research.

Synergistic efficacy of dual PI3K-d/g inhibitor Duvelisib with Bcl2 inhibitor Venetoclax in Richter's Syndrome PDX models.

S. Deaglio, F. Arruga, C. Laudanna, 2021, Blood.

Preclinical Development Preclinical Characterization of OSI-027 , a Potent and Selective Inhibitor of mTORC 1 and mTORC 2 : Distinct from Rapamycin

P. Houghton, P. Gokhale, D. Epstein, 2011 .

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

S. Thomson, D. Epstein, J. Haley, 2008, Cancer research.

Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy

D. Weaver, Hong Jiang, W. Hawkins, 2016, Nature Medicine.

A peptide histidine isoleucine/peptide histidine methionine-like peptide in the rabbit retina: Colocalization with vasoactive intestinal peptide, synaptic relationships and activation of adenylate cyclase activity

D. Marshak, J. Pachter, D. Lam, 1989, Neuroscience.

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo

N. Gibson, L. Arnold, J. Pachter, 2007, Molecular Cancer Therapeutics.

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia

A. Rao, M. Andreeff, D. Weaver, 2020, Molecular Cancer Therapeutics.

D4 dopamine receptor-selective compounds from the Chinese plant Phoebe chekiangensis

P. Dai, V. Hegde, Mahesh Patel, 1997 .

Early Path Dominance as a Principle for Neurodevelopment

Rostam M. Razban, L. Mujica-Parodi, J. Pachter, 2022, bioRxiv.

Ca2+ transients induced by thyrotropin-releasing hormone rapidly lose their ability to cause release of prolactin.

P. Dannies, J. Pachter, G. J. Law, 1989, Molecular endocrinology.

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical Models

J. Kutok, Yasmine Kieso, N. Chiorazzi, 2021 .

Abstract 4487: OSI-027, a potent and selective small molecule mTORC1/mTORC2 kinase inhibitor is mechanistically distinct from rapamycin

P. Gokhale, D. Epstein, A. Crew, 2010 .

LYMPHOID NEOPLASIA Pyk2 promotes tumor progression in multiple myeloma

N. Munshi, W. Tam, Qunli Xu, 2014 .

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

R. Vij, D. Weaver, A. Azab, 2019, Haematologica.

Thapsigargin, but not caffeine, blocks the ability of thyrotropin-releasing hormone to release Ca2+ from an intracellular store in GH4C1 pituitary cells.

M. Hanley, O. Thastrup, P. Dannies, 1990, The Biochemical journal.

Expression and Characterization of Recombinant Type 2 3α-Hydroxysteroid Dehydrogenase (HSD) from Human Prostate: Demonstration of Bifunctional 3α/17β-HSD Activity and Cellular Distribution

D. Peehl, J. Jez, Hsueh-Kung Lin, 1997 .

Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution.

D. Peehl, J. Jez, T. Penning, 1997, Molecular endocrinology.

TRH and BAY K 8644 synergistically stimulate prolactin release but not 45Ca2+ uptake.

P. Dannies, J. Pachter, G. Law, 1988, The American journal of physiology.

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells

K. Nishio, M. Kuwano, M. Ono, 2017, Oncotarget.

Inhibition of FAK kinase activity preferentially targets cancer stem cells

W. Tam, M. Wicha, Qunli Xu, 2017, Oncotarget.

Pi3k/mtor Dual Inhibitor Vs-5584 Preferentially Targets Cancer Stem Cells Introduction

Qunli Xu, D. Weaver, V. Kolev, 2022 .

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

P. Houghton, P. Gokhale, D. Epstein, 2011, Molecular Cancer Therapeutics.

Inhibition of FAK kinase activity preferentially targets cancer stem cells.

W. Tam, M. Wicha, Qunli Xu, 2017, Oncotarget.

ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.

C. Der, D. Vigil, T. Kim, 2012, Cancer research.

Therapeutics , Targets , and Chemical Biology ROCK 1 and ROCK 2 Are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion

C. Der, D. Vigil, T. Kim, 2012 .

ROCK 1 and ROCK 2 are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion

C. Der, D. Vigil, T. Kim, 2012 .

Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.

D. Werner, P. Gokhale, N. Gibson, 2011, Bioorganic & medicinal chemistry letters.

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

Adam Byron, Nick Gilbert, Valerie G. Brunton, 2015, Cell.

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

W. R. Bishop, L. Presta, Yaolin Wang, 2005, Molecular Cancer Therapeutics.

Bombesin stimulates inositol polyphosphate production in GH4C1 pituitary tumor cells: comparison with TRH.

P. Dannies, J. Pachter, G. Law, 1988, Biochemical and biophysical research communications.

The disintegrin eristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells.

E. Danen, D. Ruiter, G. V. van Muijen, 1998, Experimental cell research.

Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells

W. El-Deiry, Shengliang Zhang, Lanlan Zhou, 2020, bioRxiv.

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.

P. Tamayo, E. Ruppin, J. Lee, 2019, Cancer cell.

Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells.

W. R. Bishop, E. Maxwell, Yan Wang, 2002, Molecular cancer therapeutics.

PI 3 K / mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells

Qunli Xu, D. Weaver, V. Kolev, 2014 .

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma

L. Hazlehurst, J. Gemmer, A. Macleod, 2016, Oncogene.

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

J. Dipersio, P. Amatya, Julie K. Ritchey, 2020 .

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.

Y. Drew, N. Curtin, E. Matheson, 2019, Biochemical pharmacology.

Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

G. Merlino, A. Aplin, P. Mali, 2021, Clinical Cancer Research.

Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.

D. Epstein, Jing Wang, A. Crew, 2013, Bioorganic & medicinal chemistry letters.

Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship

Andrea I. McClatchey, J. Testa, Qunli Xu, 2014, Science Translational Medicine.

Molecular pharmacological differences between carminomycin and its analog, carminomycin-11-methyl ether, and adriamycin.

S. Crooke, J. Pachter, V. H. Duvernay, 1980, Cancer research.

Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure--activity relationships of marcellomycin and its analogues as compared to adriamycin.

S. Crooke, J. Pachter, V. H. Duvernay, 1979, Biochemistry.

DNA binding studies on several new anthracycline antitumor antibiotics II. The importance of the carbomethoxy-group as position-10 of the class II anthracycline molecule.

S. Crooke, J. Pachter, V. H. Duvernay, 1979, Molecular pharmacology.

Differential regulation of phosphoinositide and phosphatidylcholine hydrolysis by protein kinase C-beta 1 overexpression. Effects on stimulation by alpha-thrombin, guanosine 5'-O-(thiotriphosphate), and calcium.

W. R. Bishop, R. Mayer-Ezell, J. Pachter, 1992, The Journal of biological chemistry.

Overexpression of protein kinase C beta 1 enhances phospholipase D activity and diacylglycerol formation in phorbol ester-stimulated rat fibroblasts.

W. R. Bishop, I. Weinstein, J. Pachter, 1991, Proceedings of the National Academy of Sciences of the United States of America.

In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)

R. Wild, J. Pachter, E. Buck, 2007 .

Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion

K. Lim, Hong Jiang, R. Fields, 2019, Gut.

Multiple receptors coupled to adenylate cyclase regulate Na-H exchange independent of cAMP.

D. Barber, J. Pachter, M. Ganz, 1990, The Journal of biological chemistry.

Abstract 1425: Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors

J. Paradis, J. Pachter, S. Coma, 2021, Experimental and Molecular Therapeutics.

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib

A. Pettitt, D. Weaver, J. Slupsky, 2023, Scientific Reports.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

B. Győrffy, J. Heino, D. Schlaepfer, 2019, bioRxiv.

Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics.

P. Gokhale, D. Epstein, E. May, 2013, ACS medicinal chemistry letters.

Ca2+ channel agonists enhance thyrotropin-releasing hormone-induced inositol phosphates and prolactin secretion.

P. Dannies, J. Pachter, G. Law, 1991, European journal of pharmacology.

Dopamine has no effect on thyrotropin-releasing hormone mobilization of calcium from intracellular stores in rat anterior pituitary cells.

P. Dannies, J. Pachter, G. Law, 1988, Molecular endocrinology.

Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases.

J. Pachter, A. Garton, L. Castaldo, 2008, Methods in enzymology.

Early path dominance as a principle for neurodevelopment

Rostam M. Razban, L. Mujica-Parodi, J. Pachter, 2023, bioRxiv.

Pyk2 promotes tumor progression in multiple myeloma.

N. Munshi, W. Tam, Wenjing Zhang, 2014, Blood.

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.

M. Albertella, P. Gokhale, D. Epstein, 2013, Bioorganic & medicinal chemistry letters.

Compounds capable of generating singlet oxygen represent a source of artifactual data in scintillation proximity assays measuring phosphopeptide binding to SH2 domains.

R. Bryant, J. Pachter, J. J. Pai, 1999, Analytical biochemistry.

A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

W. R. Bishop, Yaolin Wang, Xiaoying Wang, 2010, Molecular Cancer Therapeutics.

Interactions Between Vasoactive Intestinal Peptide and Dopamine in the Rabbit Retina: Stimulation of a Common Adenylate Cyclase

D. M. Lam, J. Pachter, 1986, Journal of neurochemistry.

Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.

P. Gokhale, K. Foreman, Hanqing Dong, 2011, Bioorganic & medicinal chemistry letters.

In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts

B. Teicher, R. Lock, K. Evans, 2023, Pediatric blood & cancer.

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity

R. Clarke, N. Bundred, G. Farnie, 2021, npj Breast Cancer.

Cooperative Signaling between Oncostatin M, Hepatocyte Growth Factor and Transforming Growth Factor-β Enhances Epithelial to Mesenchymal Transition in Lung and Pancreatic Tumor Models

Peter Mercado, G. Argast, D. Epstein, 2010, Cells Tissues Organs.

Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions inKRASmutant cancers

G. Mills, C. Yap, Juanita Lopez, 2020 .

Abstract 1263: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy

J. Pachter, S. Coma, S. Chowdhury, 2021, Experimental and Molecular Therapeutics.

FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy

D. Weaver, Yan Wang, J. Pachter, 2015, Journal of Immunotherapy for Cancer.

Abstract 4236: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy

R. Bueno, P. Baas, Qunli Xu, 2015 .

302 FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapy

P. Baas, Qunli Xu, D. Weaver, 2014 .

Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.

M. Malkowski, T. Turek-Etienne, Yan Wang, 2004, Journal of experimental therapeutics and oncology.

PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

Qunli Xu, D. Weaver, V. Kolev, 2015, Cancer Research.

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

L. Presta, Yaolin Wang, Yan Wang, 2005, Molecular Cancer Therapeutics.

Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance.

L. Benet, J. Pachter, Ken A. Dill, 2022, Pharmacology & therapeutics.

Abstract 1525: FAK and PI3K/mTOR inhibitors target cancer stem cells: Implications for SCLC treatment strategies

Qunli Xu, V. Kolev, J. Pachter, 2015 .

Dual stromal targeting sensitizes pancreatic adenocarcinoma for anti-PD-1 therapy.

K. Chan, S. Pandol, J. Gong, 2022, Gastroenterology.

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

B. Monk, A. Oza, R. Coleman, 2022, Journal of Clinical Oncology.

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

A. Molinolo, D. Swaney, M. Ceribelli, 2023, Cell reports. Medicine.

Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target cancer stem cells.

Qunli Xu, V. Kolev, M. Keegan, 2013 .

Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.

C. Mullighan, P. Houghton, M. Churchman, 2016, JCI insight.